Dr. Rothblum-Oviatt is a Science Policy Analyst with the Rare Diseases Team (RDT) in FDA’s Center for Drug Evaluation and Research (CDER) / Office of New Drugs (OND). As a member of the RDT, Dr. Rothblum-Oviatt serves as a liaison for FDA rare disease drug development policy and programming initiatives and external stakeholder activities. Prior to joining the FDA, Dr. Rothblum-Oviatt spent 20 years in the rare disease non-profit space managing research strategies (basic, translational, clinical) and consulting on healthcare policy issues while prioritizing the patient voice.

Dr. Rothblum-Oviatt earned her PhD in biochemistry from the George Washington University in the District of Columbia but is a cell biologist by training. Her post-doctoral research, performed at the Washington University School of Medicine in St. Louis, focused on regulation of the eukaryotic cell cycle.